Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Bioequivalence Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety After Administration of TELMI ONE TAB. 80 mg and MICARDIS TAB. 80 mg(Telmisartan) in Healthy Adult Volunteers

NCT05223101 is registered in ClinicalTrials.gov with HK inno.N Corporation as lead sponsor.

NCT NCT05223101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05223101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Bioequivalence Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety After Administration of TELMI ONE TAB. 80 mg and MICARDIS TAB. 80 mg(Telmisartan) in Healthy Adult Volunteers
Lead sponsor
HK inno.N Corporation
Phase
Phase 1
Overall status
Unknown status
Start date
January 19, 2022
Completion date
July 31, 2022
Enrollment
46 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension